Last reviewed · How we verify
Spadon (CAROVERINE)
Spadon (generic name: CAROVERINE) is a caroverine drug. It is currently in Phase 2 development.
Spadon works by affecting the flow of ions and neurotransmitters in the brain.
Spadon, also known as CAROVERINE, is a small molecule drug in the caroverine class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating ion channels and affecting neurotransmitter release. Spadon's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic. Further research is needed to fully understand its pharmacology and clinical utility. As a result, key safety considerations and dosing information are not well established.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CAROVERINE |
|---|---|
| Drug class | caroverine |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a busy city with many different streets and intersections. Spadon helps control the flow of traffic by regulating the movement of ions and neurotransmitters, which are like cars and trucks that carry important messages between different parts of the brain.
Approved indications
Common side effects
- Hypoaesthesia Oral
- Paraesthesia Oral
- Product Taste Abnormal
- Somnolence
Key clinical trials
- Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions (PHASE2)
- Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (PHASE2)
- Caroverin and Inner Ear Diseases (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spadon CI brief — competitive landscape report
- Spadon updates RSS · CI watch RSS
Frequently asked questions about Spadon
What is Spadon?
How does Spadon work?
What is the generic name of Spadon?
What drug class is Spadon in?
What development phase is Spadon in?
What are the side effects of Spadon?
Related
- Drug class: All caroverine drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing